Drug Type Small molecule drug |
Synonyms Apatone, Apatone-B |
Target |
Action inhibitors |
Mechanism NF-κB inhibitors(Nuclear factor NF-kappa-B complex inhibitors), Vitamin C supplements |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC6H8O6 |
InChIKeyCIWBSHSKHKDKBQ-JLAZNSOCSA-N |
CAS Registry50-81-7 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Edema | Phase 2 | United States | 01 Oct 2010 | |
| Foreign-Body Reaction | Phase 2 | United States | 01 Oct 2010 | |
| Osteolysis | Phase 2 | United States | 01 Oct 2010 | |
| Synovitis | Phase 2 | United States | 01 Oct 2010 | |
| Prostatic Cancer | Phase 2 | United States | - | 10 Jan 2005 |
| Joint Diseases | Phase 2 | - | - | |
| Wounds and Injuries | Clinical | United States | - | |
| Polycystic Kidney Diseases | Preclinical | United States | - | - |
Phase 2 | 57 | (Oral Apatone®B) | cparezwali(vbojjpitzl) = xdkztlugdj arycgrihox (rpjkjztogp, 24.1) View more | - | 31 Jan 2018 | ||
Placebo (Placebo) | cparezwali(vbojjpitzl) = mpnsuphspm arycgrihox (rpjkjztogp, 24.9) View more |





